South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

The proposal also advises that the supply of a different insulin medicine, NovoMix 30, is due to end in 2026. Both medicines are supplied by the same company, Novo Nordisk. Heyes says Pharmac ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

They were eligible if their physician believed that they required insulin therapy ... Denmark] and NovoMix 30 FlexPen® 100 IU/ml suspension for injection in a prefilled pen [Novo Nordisk ...